O - I'm in SYN for long term unless their story changes too much from my original investment thesis. Target - $12.00 end of 2014. I believe the MS drug, though not novel, is patented tightly enough to attract buyer or partner - and those funds can develop rest of pipeline. The c-dif treatment will be HUGE. If it successfully prevents, then docs will pretty much be forced to incorporate it into standard of care for all of their immune compromised patients receiving either multiple antibiotic treatment or IV beta-lactam antibiotics. Even if their c-dif product is inexpensive - its usage as a near mandatory standard of care c-dif preventative will be extensive. Such a simple win. So...$12.00 end of 2014, mid20s by mid2015 and after their passive immunity monoclonals are shown to be effective - the price will be ONYX and SGEN high. I was in both of those for years - did well - but sold both too early. I'm holding onto this one for a long time.